标记临床研究 XOMA 深 沪
等待开盘 11-07 09:30:00 美东时间
34.07
+0.690
+2.07%
华盛通- 最 高34.71
- 今 开32.91
- 成交量 4.49万股
- 最 低 32.8896
- 昨 收 33.38
- 总市值 4.12亿
- 52周最高 39.92
- 市盈率 静 --
- 换手率 0.37%
- 52周最低 18.352
- 委 比 -69.23%
- 总股本 1208.77万
- 历史最高 191.40
- 量 比 1.06
- 振 幅 5.45%
- 历史最低 3.96
- 每 手 1
- 风险率 5.13%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Mural Oncology Shareholders Approve Takeover Of XOMA Royalty's XRA 5 Unit
Mural Oncology plc (NASDAQ:MURA) ("Mural") today announced that its shareholders have voted to approve the previously announced proposed acquisition of Mural by XRA 5 Corp. ("Sub"), a wholly owned subsidiary of XOMA
10-25 04:27
XOMA and LAVA Therapeutics Announce Amendment To Purchase Agreement; LAVA Shareholders Who Tender Their Shares Will Now Receive An Initial Cash Amount Per Share Of $1.04; Amendment To Agreement With LAVA Includes Updated CVR Terms For Tender Offer
- Amendment includes finalized cash amount and updated CVR terms for tender offer- LAVA announces new date for extraordinary general meeting of shareholdersEMERYVILLE, Calif. and UTRECHT, The Netherlands and
10-17 23:48
XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
XOMA Royalty and LAVA Therapeutics have amended their share purchase agreement. Under the amendment, LAVA shareholders tendering shares will receive $1.04 per share and a CVR entitling them to 75% of net proceeds from partnered assets and up to $0.23 per CVR based on potential liabilities. The minimum net-cash closing condition was reduced to $24.5 million. The offer expiration was extended to November 12, 2025, and LAVA shareholders supporting t...
10-17 15:45
ESSA Announces Completion of Arrangement with XenoTherapeutics
SOUTH SAN FRANCISCO, Calif., USA and VANCOUVER, BC, Canada, Oct. 9, 2025 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company") today announced the completion of XenoTherap...
10-09 19:00
ESSA Securityholders Approve Acquisition by XenoTherapeutics
SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, Oct. 6, 2025 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company") is pleased to announce that its Securityholders (as defi...
10-07 05:14
XOMA Royalty May Offer & Sell Shares Of Common Stock From Time To Time Of Up To $75M
-SEC Filing
10-04 05:51
Xoma Announces $125 Million Sales Agreements
An update from Xoma ( ($XOMA) ) is now available. On October 3, 2025, XOMA Roya...
10-04 05:50
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
XOMA Royalty and LAVA announce the extension of the tender offer for LAVA shares until October 17, 2025, originally set for October 3. The offer includes cash and a contingent value right (CVR) per share. The transaction is expected to close in Q4 2025, subject to 80% (or 75% in certain cases) of shares being tendered, shareholder approval, and other customary conditions. LAVA shareholders who have already tendered shares do not need to re-tender...
10-02 20:43
LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025
LAVA Therapeutics has canceled its Extraordinary General Meeting (EGM) scheduled for September 30, 2025, to allow further discussions with XOMA Royalty regarding the terms of their proposed transaction. Both companies remain committed to completing the deal, which is now anticipated to close in the fourth quarter of 2025. The EGM will be reconvened by early November, with details to be announced later. The cancellation aims to address potential l...
09-30 11:00
ESSA Pharma cuts shareholder payout in revised Xeno deal
ESSA Pharma (NASDAQ:EPIX) fell above 18% premarket on Wednesday after the company revised terms of its merger with biotech firm XenoTherapeutics, lowering expected shareholder payout due to potential ...
09-24 18:35
